Eisai Launches New Online Resource Helping Women Living with Metastatic Breast Cancer Navigate Their Journey

“Today is Metastatic Breast Cancer Awareness Day, an important time to recognize an overlooked group of patients who live with a complex disease that has different needs and concerns,” said Christine Verini, vice president, corporate communications and advocacy, Eisai Inc. “We are committed to supporting women by providing valuable information and educational resources that address the real-world challenges specific to living with MBC.”

Access to information is a documented need among MBC patients, with 69 percent of women perceiving this as an essential part of their journey. Similarly, 73 percent of patients report seeking information about MBC and treatment options on either a daily or weekly basis. Additional research reveals that 69 percent of women with MBC find it helpful to listen to or read about other people’s experiences with breast cancer.

“These statistics suggest the need for centralized online resources to help women with MBC better cope with their disease,” said Verini. “The launch of mbcInfoCenter.com is an important step in providing MBC patients with a better understanding of their disease and their options, as well as guiding them to communities where they can find support by sharing experiences with other patients.”

Additional resources available to patients on mbcInfoCenter.com include:

• Information on the disease and treatment options
• Overview of common side-effects and suggested side effect and pain management techniques
• Healthy lifestyle tips while living with MBC
• Strategies to manage finances throughout MBC treatment

For more information about metastatic breast cancer and resources that support these women and their loved ones, please visit mbcInfoCenter.com.

Eisai-sponsored Initiative Further Raises MBC Awareness and Amplifies the Voices of Metastatic Breast Cancer Patients
In addition to launching mbcInfoCenter.com, Eisai is also proud to sponsor the Hear My Voice campaign from Living Beyond Breast Cancer (LBBC), an effort to raise awareness for MBC and patients’ experiences through the voices of women and men living beyond the disease. Hear My Voice, which is also launching on Metastatic Breast Cancer Awareness Day, aims to educate the public about the realities of living with MBC, discuss both challenges and positive changes the diagnosis created, and provide advice for women who are newly diagnosed with MBC. To learn more about real-life MBC experiences and the Hear My Voice initiative, please visit lbbc.org/hearmyvoice.

About Metastatic Breast Cancer
Metastatic breast cancer is an advanced stage of the disease that occurs when cancer spreads beyond the breast to other parts of the body. In 2014, an estimated 232,670 women will be diagnosed with breast cancer in the United States and 40,000 women will die from the disease. It is estimated approximately 5 percent of women with breast cancer will have metastatic disease at the time of diagnosis and approximately 30 percent of all breast cancer cases will become metastatic. An estimated one in four women with metastatic breast cancer is expected to survive five years. For more information about metastatic breast cancer, please visit mbcInfoCenter.com.

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai’s global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.